Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age

NCT06618196 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

336

Enrollment

INDUSTRY

Sponsor class

Conditions

Diphtheria
Tetanus
Pertussis
Hepatitis B
Poliomyelitis
Haemophilus Influenzae Type B Infection

Interventions

BIOLOGICAL: LR20062
BIOLOGICAL: DTaP-HepB-IPV-Hib vaccine

Sponsor

LG Chem